VORASIDENIB
Vorasidenib 10 mg tablet, 30
VORASIDENIB (15437L)
15437L
Manner of administration:Oral
Restriction (Streamlined authority code: 19016)
Indication: Adult-type IDH-mutant astrocytoma or oligodendroglioma
Treatment phase: Initial treatment
Restriction (Streamlined authority code: 19035)
Indication: Adult-type IDH-mutant astrocytoma or oligodendroglioma
Treatment phase: Continuing treatment
Restriction (Streamlined authority code: 18999)
Indication: Adult-type IDH-mutant astrocytoma or oligodendroglioma
Treatment phase: Grandfather arrangements - Transitioning from non-PBS to PBS-subsidised treatment
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 2 | Max qty units: 60 | # of repeats: 5 | DPMQ: $28,947.36 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Voranigo | |||||